Takeda Research Chief Announces 2027 Retirement as Novo Nordisk Names New Global Research Lead
Takeda's head of research and development, Andy Plump, will step down in June 2027, having joined the company from Sanofi in 2015 and led R&D since late 2018. The announcement comes as Takeda celebrates two recent FDA approvals. Separately, Novo Nordisk has appointed a new global research head, though details were not provided in the brief item.
Andy Plump's tenure at Takeda will span over a decade, concluding in mid-2027. He assumed leadership of the research and development division in late 2018, following his arrival from Sanofi in 2015. This planned succession occurs shortly after the company secured two recent approvals from the U.S. Food and Drug Administration.
In a parallel development, Novo Nordisk has named a new global research lead, although specific details about this appointment remain undisclosed. These leadership shifts within major pharmaceutical firms highlight ongoing changes in the drug development landscape.
The upcoming leadership transitions at Takeda and Novo Nordisk could influence the future trajectory of drug development pipelines. Patients relying on emerging therapies may experience shifts in research priorities or timelines as new executives take charge. Investors and healthcare professionals might observe changes in strategic focus, potentially affecting the speed and nature of future approvals. While Takeda's recent FDA wins suggest current strength, the 2027 handover may introduce a period of recalibration, and Novo Nordisk's new research lead could bring novel approaches to the field.